Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New highly specific agonistic peptides for human melanocortin MC1 receptor
Autore:
Szardenings, M; Muceniece, R; Mutule, I; Mutulis, F; Wikberg, JES;
Indirizzi:
Uppsala Univ, Dept Pharmaceut Pharmacol, SE-75124 Uppsala, Sweden Uppsala Univ Uppsala Sweden SE-75124 Pharmacol, SE-75124 Uppsala, Sweden Melacure Therapeut AB, SE-75183 Uppsala, Sweden Melacure Therapeut AB Uppsala Sweden SE-75183 , SE-75183 Uppsala, Sweden Pharmaceut Pharmacol, SE-75124 Uppsala, Sweden Pharmaceut Pharmacol Uppsala Sweden SE-75124 l, SE-75124 Uppsala, Sweden
Titolo Testata:
PEPTIDES
fascicolo: 2, volume: 21, anno: 2000,
pagine: 239 - 243
SICI:
0196-9781(200002)21:2<239:NHSAPF>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
MOLECULAR-CLONING; RADIOLIGAND BINDING; ALPHA-MELANOTROPIN; MSH ANALOGS; EXPRESSION; CELLS; DISCOVERY; SUBTYPES; HORMONE; FAMILY;
Keywords:
melanocortin receptors; melanocyte stimulating hormone; receptor selective peptides;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Wikberg, JES Pharmaceut Pharmacol, SE-75124 Uppsala, Sweden Pharmaceut Pharmacol Uppsala Sweden SE-75124 ppsala, Sweden
Citazione:
M. Szardenings et al., "New highly specific agonistic peptides for human melanocortin MC1 receptor", PEPTIDES, 21(2), 2000, pp. 239-243

Abstract

A peptide with very high specificity for the human melanocortin MC1 receptor identified by phage display was used as a lead for the design of new peptides. Two new peptides, MS05 and MS09, were synthesized and found to bind with sub-nanomolar affinities to the MC1 receptor. Both these peptides showed strong agonistic activity at the MC, receptor. The MS05 was the most MC1receptor selective as it showed virtually no binding affinity for the MC4 and MC5 receptors and only micromolar affinity for the MC3 receptor. The selectivity and potency of the new peptides make them potent tools For studies of MC1 receptors, as well as novel potential candidate drugs for the treatment of inflammatory conditions. (C) 2000 Elsevier Science Inc. All rightsreserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 09:06:46